Abstract The immune landscape of late-stage liver cancer is featured by severe immunosuppression that is characterized by poor immunogenicity, T-cell exhaustion, and infiltration of a large number of immunosuppressive cells, leading to compromised therapeutic efficacy of mainstream immunotherapies. Herein, we developed a pleiotropic immunoferroptotic mobilization strategy to treat intractable advanced liver cancer. In this study, immunogenic bacteria-derived outer membrane vesicles (OMVs) were exploited as a vector to deposit Cu and Mn with mixed valence states via one-step biomineralization, followed by platelet membrane camouflage to enhance the circulation time and reduce systemic side effects of the metal biomineralized OMVs, which are denoted as OPCM. Mechanistically, the metal-deposited OPCM possesses POD, CAT, and GPX-like activities, thereby stimulating immunogenic ferroptosis, cGAS-STING activation, and tumor hypoxia alleviation, ultimately leading to pleiotropic immunoferroptotic mobilization to combat tumor growth, recurrence, and metastasis. Notably, the combination with typical αPD-L1 augmented the tumor suppression effect, since the administration of αPD-L1 not only rescued exhausted T cells, but also amplified the intensity of ferroptosis due to IFN-γ secretion by activated T cells. Overall, the metal biomineralized OPCMs in combination with αPD-L1 formed a closed-loop therapy that cycles from immunotherapy and ferroptosis therapy, providing new insights for treating immunosuppressive liver cancer.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: